| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787535 | Journal of Thoracic Oncology | 2018 | 28 Pages |
Abstract
The data on the Italian expanded access program in populations with nonsquamous NSCLC suggest that subgroups of patients could benefit differently from nivolumab according to their EGFR mutational status and smoking habits. These results warrant further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Marina Chiara MD, Alain Jonathan MD, Francesco MD, Rita MD, Hector MD, Stefano MD, Francesco MD, Daniele MD, Livio MD, Carmelo MD, Enrico MD, Editta MD, Silvia MD, Giovanni Luca MD, Paola MD, Enrico MD, Carmine MD, Gianpiero MD, Filippo MD,